Integrative molecular network analysis identifies emergent enzalutamide resistance mechanisms in prostate cancer

nork King, Carly J., Woodward, Josha, Schwartzman, Jacob, Coleman, Daniel J., Lisac, Robert, Wang, Nicholas J., Van Hook, Kathryn, Gao, Lina, Urrutia, Joshua, Dane, Mark A., Heiser, Laura M., Alumkal, Joshi J.
Argitaratua izan da Oncotarget (2017)

Maintenance of MYC expression promotes de novo resistance to BET bromodomain inhibition in castration-resistant prostate cancer

nork Coleman, Daniel J., Gao, Lina, Schwartzman, Jacob, Korkola, James E., Sampson, David, Derrick, Daniel S., Urrutia, Joshua, Balter, Ariel, Burchard, Julja, King, Carly J., Chiotti, Kami E., Heiser, Laura M., Alumkal, Joshi J.
Argitaratua izan da Sci Rep (2019)

BET Bromodomain Inhibition Blocks the Function of a Critical AR-Independent Master Regulator Network in Lethal Prostate Cancer

nork Coleman, Daniel J., Gao, Lina, King, Carly J., Schwartzman, Jacob, Urrutia, Joshua, Sehrawat, Archana, Tayou, Junior, Balter, Ariel, Burchard, Julja, Chiotti, Kami E., Derrick, Daniel S., Sun, Duanchen, Xia, Zheng, Heiser, Laura M., Alumkal, Joshi J.
Argitaratua izan da Oncogene (2019)

Alternative splicing of LSD1+8a in neuroendocrine prostate cancer is mediated by SRRM4

nork Coleman, Daniel J., Sampson, David A., Sehrawat, Archana, Kumaraswamy, Anbarasu, Sun, Duanchen, Wang, Yuzhuo, Schwartzman, Jacob, Urrutia, Joshua, Lee, Ahn R., Coleman, Ilsa M., Nelson, Peter S., Dong, Xuesen, Morrissey, Colm, Corey, Eva, Xia, Zheng, Yates, Joel A., Alumkal, Joshi J.
Argitaratua izan da Neoplasia (2020)

Cellular androgen content influences enzalutamide agonism of F877L mutant androgen receptor

nork Coleman, Daniel J., Van Hook, Kathryn, King, Carly J., Schwartzman, Jacob, Lisac, Robert, Urrutia, Joshua, Sehrawat, Archana, Woodward, Josha, Wang, Nicholas J., Gulati, Roman, Thomas, George V., Beer, Tomasz M., Gleave, Martin, Korkola, James E., Gao, Lina, Heiser, Laura M., Alumkal, Joshi J.
Argitaratua izan da Oncotarget (2016)

Copy Number Loss of 17q22 is Associated with Enzalutamide Resistance and Poor Prognosis in Metastatic Castration-Resistant Prostate Cancer

nork Guan, Xiangnan, Sun, Duanchen, Lu, Eric, Urrutia, Joshua A., Reiter, Robert Evan, Rettig, Matthew, Evans, Christopher P., Lara, Primo, Gleave, Martin, Beer, Tomasz M., Thomas, George V., Huang, Jiaoti, Aggarwal, Rahul R., Quigley, David A., Foye, Adam, Chen, William S., Youngren, Jack, Weinstein, Alana S., Stuart, Joshua M., Feng, Felix Y., Small, Eric J., Xia, Zheng, Alumkal, Joshi J.
Argitaratua izan da Clin Cancer Res (2020)

LSD1 activates a lethal prostate cancer gene network independently of its demethylase function

nork Sehrawat, Archana, Gao, Lina, Wang, Yuliang, Bankhead, Armand, McWeeney, Shannon K., King, Carly J., Schwartzman, Jacob, Urrutia, Joshua, Bisson, William H., Coleman, Daniel J., Joshi, Sunil K., Kim, Dae-Hwan, Sampson, David A., Weinmann, Sheila, Kallakury, Bhaskar V. S., Berry, Deborah L., Haque, Reina, Van Den Eeden, Stephen K., Sharma, Sunil, Bearss, Jared, Beer, Tomasz M., Thomas, George V., Heiser, Laura M., Alumkal, Joshi J.
Argitaratua izan da Proc Natl Acad Sci U S A (2018)

Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance

nork Alumkal, Joshi J., Sun, Duanchen, Lu, Eric, Beer, Tomasz M., Thomas, George V., Latour, Emile, Aggarwal, Rahul, Cetnar, Jeremy, Ryan, Charles J., Tabatabaei, Shaadi, Bailey, Shawna, Turina, Claire B., Quigley, David A., Guan, Xiangnan, Foye, Adam, Youngren, Jack F., Urrutia, Joshua, Huang, Jiaoti, Weinstein, Alana S., Friedl, Verena, Rettig, Matthew, Reiter, Robert E., Spratt, Daniel E., Gleave, Martin, Evans, Christopher P., Stuart, Joshua M., Chen, Yiyi, Feng, Felix Y., Small, Eric J., Witte, Owen N., Xia, Zheng
Argitaratua izan da Proc Natl Acad Sci U S A (2020)